China Biologic Products Holdings, Inc. (CBPO) At $85.84 Forms Bottom; Cellectar Biosciences (CLRB) Shorts Decreased By 0.77%

April 14, 2018 - By Dolores Ford

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Logo

China Biologic Products Holdings, Inc. (CBPO) formed multiple bottom with $80.69 target or 6.00% below today’s $85.84 share price. China Biologic Products Holdings, Inc. (CBPO) has $2.84 billion valuation. The stock increased 0.27% or $0.23 during the last trading session, reaching $85.84. About 83,025 shares traded. China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has declined 18.54% since April 14, 2017 and is downtrending. It has underperformed by 30.09% the S&P500.

Cellectar Biosciences Inc (NASDAQ:CLRB) had a decrease of 0.77% in short interest. CLRB’s SI was 1.08M shares in April as released by FINRA. Its down 0.77% from 1.09M shares previously. With 353,700 avg volume, 3 days are for Cellectar Biosciences Inc (NASDAQ:CLRB)’s short sellers to cover CLRB’s short positions. The stock increased 3.31% or $0.04 during the last trading session, reaching $1.25. About 193,692 shares traded. Cellectar Biosciences, Inc. (NASDAQ:CLRB) has declined 51.67% since April 14, 2017 and is downtrending. It has underperformed by 63.22% the S&P500.

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company has market cap of $21.74 million. The firm offers CLR 131, a PDC cytotoxic radioisotope product candidate, which is in Phase I clinical study for the treatment of relapse or refractory multiple myeloma, as well as in Phase II clinical study for the treatment of B-cell malignancies; and CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease. It currently has negative earnings. It also provides CLR 124, a cancer-targeting positron emission tomography imaging PDC for the selective detection of tumors and metastases in a range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.

Analysts await China Biologic Products Holdings, Inc. (NASDAQ:CBPO) to report earnings on May, 2. They expect $1.28 EPS, down 3.03% or $0.04 from last year’s $1.32 per share. CBPO’s profit will be $42.41M for 16.77 P/E if the $1.28 EPS becomes a reality. After $0.90 actual EPS reported by China Biologic Products Holdings, Inc. for the previous quarter, Wall Street now forecasts 42.22% EPS growth.

Among 2 analysts covering China Biologic Products (NASDAQ:CBPO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. China Biologic Products has $162 highest and $97.0 lowest target. $101’s average target is 17.66% above currents $85.84 stock price. China Biologic Products had 8 analyst reports since September 4, 2015 according to SRatingsIntel. Jefferies maintained China Biologic Products Holdings, Inc. (NASDAQ:CBPO) on Friday, September 4 with “Buy” rating. The firm earned “Buy” rating on Friday, October 13 by Jefferies. Jefferies maintained China Biologic Products Holdings, Inc. (NASDAQ:CBPO) rating on Monday, June 12. Jefferies has “Buy” rating and $14000 target. On Thursday, August 3 the stock rating was maintained by Jefferies with “Buy”. The firm has “Buy” rating given on Thursday, March 15 by Jefferies. Jefferies maintained the shares of CBPO in report on Tuesday, September 12 with “Buy” rating.

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Dolores Ford

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: